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nucleotide substitutions in position 198 
(T→C) and in position 136 (A→G) of 
the 249-bp fragment. The remaining 
sample showed 100% identity with 
B. henselae strains Brazil-1 and 45-
00249 (GenBank accession nos. 
HQ012580 and GQ225709). 
Four of the 56 successfully 
sequenced samples (7.14%; all 
samples from nymphs) showed the 
sequence pattern of B. grahamii. One 
sample revealed 100% identity with 
B. grahamii (GenBank accession no. 
EU014266); the remaining 3 samples 
showed an identity of 98% with 
the B. grahamii strain Hokkaido-1 
(GenBank accession no. AB426652) 
and 99% (T→C in position 93) 
with a sequence described as B. 
grahamii–like (GenBank accession 
no. AY435122). Sequences obtained 
in this study (deposited in GenBank 
under accession nos. JQ770304 
and JK758018) support the genetic 
variability of Bartonella spp., as 
demonstrated by others (5,7,8).
It remains unclear whether 
ticks are involved in transmission 
of pathogenic Bartonella spp. to 
humans under natural conditions. 
However, the total prevalence rate of 
4.76% (100/2,100) questing I. ricinus 
ticks infected with B. henselae and 
B. grahamii highlights the need for 
public awareness and draws attention 
to the possibility of an infection 
with zoonotic Bartonella spp. after 
a tick bite (3,4). B. henselae, the 
predominantly identifi ed species, 
has been associated with cat scratch 
disease, peliosis hepatis, and bacillary 
angiomatosis in humans. Eskow et al. 
(3) also connected chronic symptoms 
of Lyme disease to co-infections with 
Borrelia burgdorferi and B. henselae. 
B. grahamii has been associated 
with neuroretinitis and ocular artery 
thrombosis in humans (9,10). The 
potential risk for zoonotic Bartonella 
spp. infection in urban recreation areas 
should not be underestimated.
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Viremia in Young 
Children, Ghana
To the Editor: Establishment 
of viremia is a characteristic feature 
of infection with human parvovirus 
4 (PARV4). In northern Europe, 
PARV4 (human partetravirus) is 
primarily transmitted by blood-borne 
routes (1,2). In other areas (southern 
Europe, western Africa, South Africa, 
Asia) infection seems to be more 
widespread, suggesting alternative 
modes of virus acquisition (3–6).
We reported PARV4 genotype 
3 viremia in young children with 
unknown parenteral blood exposure 
from the rural Ashanti region of 
Ghana (7). In that study, 2 (2.1%) of 
94 children (median age 14.9 months) 
and 22 (11.9%) of 185 children 
(median age 24.0 months) were virus 
positive (ages of the 2 virus-positive 
children from the younger cohort 
14.9 and 15.6 months). Because the 
number of infants was small in that 
study, we extended our investigations 
on PARV4 viremia to an additional 
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cohort of 15-month-old children from 
the same study group.
Plasma samples from 361 
randomly selected children (191 
girls) were tested. Specimens were 
collected during January–December 
2004 during a trial of intermittent 
preventive malaria treatment in the 
rural Afi gya Sekyere District, Ashanti 
Region, Ghana (7). Plasma samples 
were analyzed because of limited 
availability of whole blood samples. 
Median   age of children was 14.9 
months (range 13.8–17.5 months, 
interquartile range 14.5–15.2 months).
Nucleic acid was prepared from 
200-μL plasma samples by using 
the NucliSENS EasyMAG system 
(bioMérieux, Nürtingen, Germany). 
All samples were analyzed by using 2 
real-time PCRs and primers described 
elsewhere (7,8). The limit of detection 
was ≈200 plasmid copies/mL. Strict 
precautions were applied during 
plasma handling and amplifi cation to 
avoid false-positive results.
PARV4 genotype 3 DNA was 
detected in plasma of 32 (8.9%) of 361 
children. Viral load ranged from ≈200 
copies/mL to 3.0 × 104 copies/mL 
(Figure). Median viral load was 453 
copies/mL. Nucleotide sequencing 
of   screening PCR amplicons and 
additional genomic regions amplifi ed 
from 6 plasma samples identifi ed 
the viruses as PARV4 genotype 3 
(GenBank accession nos.   JN183933–
JN183938). There was no association 
between history of fever, anemia, or 
erythema in children with or without 
PARV4 viremia (p>0.05, by χ2 test).
PARV4 viremia status was 
already known for 78 children 24 
months of age (7). These data enabled 
comparison of viremia at 2 time points 
(24 months and 15 months of age). Of 
these 78 children, 10 showed viremia 
(viral load range 4.0 × 102–1.4 × 104 
copies/mL) and 3 (3.8%) had viremia 
at both time points and identical viral 
nucleotide sequences (time between 
bleedings 8.7 months for 2 children 
and 9.0 months for 1 child). However, 
only short genomic regions (780 nt 
for 1 child, 599 nt for a second child, 
and 95 nt for a third child) could be 
amplifi ed and sequenced because of 
low viral loads. Four children had 
positive results in the fi rst sample, and 
3 had positive results in the second 
sample.
Because comparison of large 
and contiguous parts of the viral 
genomes within each sample pair 
was not possible and serologic data 
were lacking, PARV4 positivity over 
a 9-month period can be interpreted 
by 3 hypotheses. First, detection 
of PARV4 DNA over time might 
represent long-term viremia after 
infection, similar to observations in 
human parvovirus B19 infection. 
Second, demonstration of PARV4 
during widely spaced intervals might 
indicate endogenous reactivation of 
viremia. Third, exogenous reinfection 
might have occurred.
PARV4 viremia was detected in a 
study in the United Kingdom among 
110 PARV4-negative persons with 
hemophilia screened over 5 years for 
PARV4 viremia and seroconversion 
(IgG and IgM) (9). Nine patients who 
seroconverted were identifi ed, and 
1 had PARV4 viremia (genotype 1) 
over an 8-month period. Viral loads 
for this patient were low (<103 copies/
mL), a fi nding similar to ours for the 
3 children. However, negative IgM 
results in the person with hemophilia 
suggest that the sampling window 
might have missed the acute infection. 
Comparison of results of our 
study with those of our previous 
study (7) showed 2 differences. First, 
frequency of viremia in children tested 
previously at 15 months of age was 
lower (2.1%, 2/94) than in the children 
in this study (8.9%). Second, median 
viral loads differed by nearly 1 log10, 
with the higher concentrations in the 
previous study analyzing EDTA whole 
blood. Whether these differences 
were caused by the relatively small 
number of children included by or 
by the fact that whole blood samples 
were compared with plasma samples 
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Figure. Parvovirus 4 DNA loads in virus-positive plasma specimens from children compared 
with those in whole blood samples previously tested (7), Ghana. Virus concentrations 
are given on a log scale on the y-axis. Each dot represents 1 specimen. Horizontal lines 
represent median values for each sample group. Children whose plasma was tested had 
a median age of 15 months, and children whose whole blood was tested had a median 
age of either 15 or 24 months. Viral load data (i. e., median viral load and range) for the 2 
groups of whole blood samples have been reported (7) and were included for comparison 
with plasma data from this study.
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remains to be clarifi ed. However, our 
previous hypothesis that prenatal or 
perinatal transient infection was an 
unlikely mode of virus acquisition 
needs to be modifi ed because PARV4 
infection in newborns has recently 
been demonstrated (10). 
Although we lacked IgM and IgG 
serologic data to interpret our fi ndings, 
our study suggests that PARV4 genotype 
3 infection might be characterized 
by viral persistence, reactivation, or 
reinfection. Additional longitudinal 
studies, including serologic testing for 
short intervals, are needed to determine 
the pathogenesis and potential public 
health role of PARV4 infection.
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Republic of the 
Congo
To the Editor: Salmonella enteri-
ca serotype Typhi and the nontyphoid 
S. enterica (NTS) are leading causes 
of bacteremia in sub-Saharan Africa, 
but little information is available from 
central Africa (1,2). We describe an 
epidemic increase of S. enterica bacte-
remia in Kisantu in southwestern Dem-
ocratic Republic of the Congo (DRC).
The Hospital of Saint Luc in 
Kisantu is a 274-bed referral hospi-
tal serving a community of 150,000 
inhabitants. As part of an ongoing 
microbiological surveillance study 
in DRC (3), we identifi ed pathogens 
grown from blood cultures (BacT/
ALERT; bioMérieux, Marcy L’Etoile, 
France) and assessed them for antimi-
crobial drug susceptibility (Vitek II 
system; bioMérieux) (4) and serotype 
(Sifi n, Berlin, Germany). We deter-
mined MICs for nalidixic acid, cipro-
fl oxacin, and chloramphenicol using 
the Etest macromethod (bioMérieux). 
For salmonella isolates, we defi ned 
decreased ciprofl oxacin susceptibil-
ity as an isolate with an MIC >0.064 
mg/L (5) and multidrug resistance 
(MDR) as co-resistance of the isolate 
to ampicillin, chloramphenicol, and 
trimethoprim/sulfamethoxazole (6). 
Screening for mutations causing de-
creased ciprofl oxacin susceptibility 
included assessment of the quinolone 
resistance–determining regions of the 
gyrA, gyrB, and parC genes and the 
plasmid-mediated qnrA, qnrB, and 
qnrS genes (7). Multilocus variable-
number tandem-repeat analysis was 
performed on a subset of 37 S. enteri-
ca ser. Enteritidis isolates (8).
The pathogens isolated were S. 
enterica ser. Typhi (n = 17, 14.4%), 
Enteritidis (n = 79, 67.0%), and Ty-
phimurium (n = 22, 18.6%). The in-
creased incidence of S. enterica bac-
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